𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics of various single intravenous and oral doses of omeprazole

✍ Scribed by T. Andersson; C. Cederberg; C. G. Reg»rdh; I. Sk»nberg

Publisher
Springer
Year
1990
Tongue
English
Weight
269 KB
Volume
39
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

✦ Synopsis

The influence of dose on the kinetics of omeprazole and two of its metabolites, hydroxyomeprazole and the sulphone, has been studied. Ten healthy subjects were given omeprazole 10 and 40 mg iv and 10, 40 and 90 mg orally. No significant dose-related difference in any parameter calculated from the iv experiments was detected. Following the oral solutions, however, there was a dose-dependent increase in systemic availability, probably due to saturable first-pass elimination. The AUC of the sulphone also seemed to increase non-linearly with increasing dose, and that of the hydroxyomeprazole increased in proportion to dose. The slight dose-dependency of the bioavailability of the solution is considered to be of no or limited clinical relevance. Furthermore, since omeprazole is given orally as slowly absorbed enteric coated granules in the dose of 20 mg o.d., the potential for dose-dependent kinetics in clinical practice would be much less than in the present study.

📜 SIMILAR VOLUMES

Pharmacokinetics of deramciclane in dogs
Pharmacokinetics of deramciclane in dogs after single oral and intravenous dosing and multiple oral dosing
✍ Harri Kanerva; Hannele Huuskonen; Anneli Alhonen-Raatesalmi; Timo Nevalainen; Ar 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 2 views

The pharmacokinetics of a new serotonin 5-HT 2 antagonist, deramciclane, was studied. Single oral doses of 1, 3, 6 and 10 mg kg -1 and intravenous doses of 1, 3 and 6 mg kg -1 were administered in beagle dogs. Moreover, the steady state pharmacokinetics of 1, 3 and 6 mg kg -1 doses were studied. Der

Pharmacokinetic and pharmacodynamic stud
Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses
✍ Boo Edgar; Carl G. Regårdh; Per Lundborg; SÖRen Romare; Gunnar Nyberg; Ola Rönn 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 607 KB

The objective of this single-dose study was to evaluate the pharmacokinetics and haemodynamic changes in healthy male subjects following the administration of three oral ( 5 , 15, and 40mg) and two intravenous (1 and 3mg) doses of felodipine, a new calcium antagonist with a selective effect on the p

Single intravenous dose and steady-state
Single intravenous dose and steady-state oral dose pharmacokinetics of nicardipine in healthy subjects
✍ John G. Wagner; Teck L. Ling; Edward J. Mroszczak; Donna Freedman; Ann Wu; Bee H 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 617 KB

Nicardipine HCI oral doses (10-40 mg) were administered sequentially to six healthy subjects. For each regimen the capsule dose was administered every 8 hours (q 8 h) for 3 days and the plasma profiles of nicardipine and its pyridine analogue (M5) were determined following the last dose on day 4. St

PHARMACOKINETICS AND SAFETY OF SINGLE IN
PHARMACOKINETICS AND SAFETY OF SINGLE INTRAVENOUS AND ORAL DOSES OF DOLASETRON MESYLATE IN HEALTHY WOMEN
✍ ANTHER C. F. KEUNG; HÉLÈNE LANDRIAULT; MARC LEFEBVRE; DENIS GOSSARD; ELLEN E. DE 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 2 views

Twenty-four healthy women received 2´4 mg kg 71 dolasetron mesylate (1´8 mg kg 71 dolasetron base) by a 10 min intravenous administration and by oral administration. Pharmacokinetics of dolasetron and of its active reduced metabolite MDL 74 156 were monitored for 48 h in plasma. Urine was collected

Pharmacokinetics and safety of single or
Pharmacokinetics and safety of single oral doses of lomefloxacin
✍ Dr. Irwin S. Morse 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB 👁 2 views

The pharmacokinetics of 100 mg, 200 mg, 400 mg, 600 mg, and 800 mg of lomefloxacin, a quinolone antimicrobial, were examined in a single sequential rising dose, placebocontrolled, crossover study. Each of 30 healthy male subjects (6 per group) received placebo and one dose of lomefloxacin, separated